DE102007044582A1 - Composition for wound treatment in the human area - Google Patents

Composition for wound treatment in the human area Download PDF

Info

Publication number
DE102007044582A1
DE102007044582A1 DE102007044582A DE102007044582A DE102007044582A1 DE 102007044582 A1 DE102007044582 A1 DE 102007044582A1 DE 102007044582 A DE102007044582 A DE 102007044582A DE 102007044582 A DE102007044582 A DE 102007044582A DE 102007044582 A1 DE102007044582 A1 DE 102007044582A1
Authority
DE
Germany
Prior art keywords
composition
wound treatment
wound
human area
wounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102007044582A
Other languages
German (de)
Inventor
Peter G Deckner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deckner Peter G Dr med
Original Assignee
Deckner Peter G Dr med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deckner Peter G Dr med filed Critical Deckner Peter G Dr med
Priority to DE102007044582A priority Critical patent/DE102007044582A1/en
Priority to PCT/DE2008/001083 priority patent/WO2009036714A1/en
Publication of DE102007044582A1 publication Critical patent/DE102007044582A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Es wird eine Zusammensetzung für Wundbehandlungen im Humanbereich angegeben, die Hyaluronsäure, Harnstoff und kolloidales Silber enthält.A human wound treatment composition containing hyaluronic acid, urea and colloidal silver is disclosed.

Description

Die vorliegende Erfindung betrifft Zusammensetzungen zur Behandlung von Wunden, insbesondere schlecht oder nicht heilender offener Wunden im Humanbereich.The The present invention relates to compositions for treatment of wounds, especially bad or non-healing open wounds in the human area.

Es ist bekannt, dass bei Menschen Wunden auftreten können, deren Heilung sich über Jahre hinzieht oder überhaupt nicht erreicht werden kann, sodass diese Wunden chronisch offen bleiben.It it is known that wounds can occur in people their healing goes on for years or even at all can not be achieved, so that these wounds open chronically stay.

Für alle aus dem Stand der Technik bekannten Zusammensetzungen ist leider zu sagen, dass ihre Wirksamkeit zwar im Einzelfall gegeben sein kann, auf breiter Basis sind sie aber nicht wirksam, was durch die nach wie vor enorme Zahl an Patienten mit schlecht oder nicht verheilenden Wunden zu sehen ist.For all known from the prior art compositions is unfortunately to say that their effectiveness may be given on a case-by-case basis, on a broad basis, however, they are not effective, which is due to the as before an enormous number of patients with bad or non-healing Wounds can be seen.

Eine Behandlungslösung zur chronischen Wundbehandlung ist aus der DE 101 40 623 A1 zu entnehmen. Die Behandlungslösung ist eine wässrige Lösung, die pro Liter Lösung neben Wasser und vorzugsweise Schwefelsäure 10 bis 100 mg Zink, 6,5 bis 65 mg Eisen und in einer Weiterentwicklung den Wachstumsfaktor PDGF enthält. Der Anteil an Säure ist so eingestellt, dass der pH-Wert zwischen 2,5 und 3,5 liegt.A treatment solution for chronic wound treatment is from the DE 101 40 623 A1 refer to. The treatment solution is an aqueous solution containing per liter of solution besides water and preferably sulfuric acid 10 to 100 mg of zinc, 6.5 to 65 mg of iron and in a further development the growth factor PDGF. The proportion of acid is adjusted so that the pH is between 2.5 and 3.5.

Eine Zusammensetzung für Wundbehandlungen mit einem Anteil an Silbersalzverbindungen ist aus der WO 2006/034249 A2 zu entnehmen.A composition for wound treatments containing a proportion of silver salt compounds is known from WO 2006/034249 A2 refer to.

Aufgabe der Erfindung ist es, eine Zusammensetzung für Wundbehandlungen im Humanbereich zu benennen, mit der rasche Heilungserfolge auch bei chronischen Wunden erzielt werden.task The invention is a composition for wound care to name in the human field, with the rapid healing success also to be achieved in chronic wounds.

Die Aufgabe wird gelöst mit den Merkmalen der Unteransprüche. Vorteilhafte, nicht platt selbstverständliche Weiterbildungen sind Gegenstand der Unteransprüche.The The problem is solved with the features of the subclaims. Advantageous, not self-evident further developments are the subject of the dependent claims.

Der Erfinder hat nun in überraschender Weise herausgefunden, dass die zuvor geschilderte Aufgabenstellung dadurch gelöst werden kann, dass zu dem vorgenannten Zweck eine Zusammensetzung bereitgestellt wird, die Hyaluronsäure, Harnstoff und kolloidales Silber enthält.Of the Inventor has now surprisingly found that solved the previously described task may be that a composition provided for the above purpose which is hyaluronic acid, urea and colloidal silver contains.

Es entfallen dabei auf 100 g der Zusammensetzung 0 g bis 0,9 g, bevorzugt 0,01 g bis 0,15, besonders bevorzugt 0,05 g bis 0,07 g Hyaluronsäure, 0,1 g bis 40 g, bevorzugt 10 g bis 30 g, besonders bevorzugt 17 g bis 19 g Harnstoff und 0,01 g bis 2 g, bevorzugt 0,1 g bis 0,2 g, besonders bevorzugt 0,125 g kolloidales Silber. Es kann jedoch einzelfallbezogen oder anwendungsbedingt erforderlich sein, von den vorgenannten Mengen abzuweichen, ohne dass dadurch der Fachmann die vorliegende Erfindung verlässt.It accounted for 100 g of the composition 0 g to 0.9 g, preferably 0.01 g to 0.15, more preferably 0.05 g to 0.07 g of hyaluronic acid, 0.1 g to 40 g, preferably 10 g to 30 g, more preferably 17 g to 19 g of urea and 0.01 g to 2 g, preferably 0.1 g to 0.2 g, especially preferably 0.125 g of colloidal silver. However, it may be case by case or required by the application, from the aforementioned quantities without thereby making the skilled person the present invention leaves.

Die Zusammensetzung enthält neben den vorgenannten Stoffen mindestens einen physiologisch und pharmakologisch unbedenklichen Träger oder Exzipienten.The Composition contains in addition to the aforementioned substances at least one physiologically and pharmacologically acceptable Carrier or excipient.

Neben den oben genannten Wirk und/oder Inhaltsstoffen kann die erfindungsgemäße Zusammensetzung weitere, dem Fachmann geläufige, Wirk- und/oder Inhaltsstoffe enthalten, insbesondere Verarbeitungshilfsstoffe, Stabilisatoren, Emulgatoren, Antiseptika, Antioxidantien, Konservierungsstoffe, Feuchthaltemittel oder dergleichen.Next the above active ingredients and / or ingredients, the inventive Composition of other active substances known to the person skilled in the art. and / or ingredients, in particular processing aids, Stabilizers, Emulsifiers, Antiseptics, Antioxidants, Preservatives, Humectants or the like.

Die erfindungsgemäße Zusammensetzung kann als Spray, Creme, Salbe, Gel, Suspension, Emulsion, Badezusatz, Pulver, Puder, Waschlotion, Tinktur, Gaze, Wundauflage, getränkte Wundauflage, Schaum, Schwamm, Sonnenschutzmittel, Fettstift oder Spüllösung vorliegen. Zu näheren Einzelheiten zu den Begriffen Salbe, Paste, Creme, Gel wird auf die einschlägigen Stichworte in Römpp, Lexikon Chemie, 10. Auflage, Georg Thieme Verlag, Stuttgart/New York verwiesen.The composition according to the invention may be in the form of a spray, cream, ointment, gel, suspension, emulsion, bath additive, powder, powder, washing lotion, tincture, gauze, wound dressing, impregnated wound dressing, foam, sponge, sunscreen, lipstick or rinsing solution. For more details on the terms ointment, paste, cream, gel is on the relevant keywords in Römpp, Lexikon Chemie, 10th edition, Georg Thieme Verlag, Stuttgart / New York directed.

Die Zusammensetzung bewirkt in ihren Anwendungsformen eine lokale Antibinse (Keimfreiheit), eine Wundreinigung, die Auflösung von Nekrosen, eine Granulationsförderung, den Schutz der Wunde und der Wundumgebung sowie eine Epithelisierung (stabile Festigung des Zellkomplexes).The In its application form composition causes a local antibinse (Germ-free), a wound cleansing, the dissolution of necroses, a granulation promotion, the protection of the wound and the Wound environment and epithelization (stable consolidation of the cell complex).

Die Zusammensetzung in Sprayform ermöglicht die Verwendung einer Knopfsonde, mit der das Spray z. B. bei Fisteln in Fistelkanäle, in Wundtaschen, in tiefe und zerklüftete Wunden, in den Analbereich, auf schlecht zugängliche Wunden, in Körperhöhlen und auf Druckstellen appliziert werden kann.The Composition in spray form allows the use a button probe with which the spray z. In fistulas in fistula canals, in wound bags, in deep and ragged wounds, in the Anal area, on badly accessible wounds, in body cavities and can be applied to pressure points.

Mit Hilfe der erfindungsgemäßen Zusammensetzungen ist es möglich, auch jahrelang offene Wunden innerhalb weniger Monate zu heilen.With Help the compositions of the invention It is also possible for years to have open wounds within to heal less months.

ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDE IN THE DESCRIPTION

Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.

Zitierte PatentliteraturCited patent literature

  • - DE 10140623 A1 [0004] - DE 10140623 A1 [0004]
  • - WO 2006/034249 A2 [0005] - WO 2006/034249 A2 [0005]

Zitierte Nicht-PatentliteraturCited non-patent literature

  • - Römpp, Lexikon Chemie, 10. Auflage, Georg Thieme Verlag, Stuttgart/New York [0012] - Römpp, Lexikon Chemie, 10th edition, Georg Thieme Verlag, Stuttgart / New York [0012]

Claims (4)

Zusammensetzung für Wundbehandlungen im Humanbereich, dadurch gekennzeichnet, dass sie je 100 g Zusammensetzung 0 g bis 0,9 g, bevorzugt 0,01 g bis 0,15 g, besonders bevorzugt 0,05 g bis 0,07 g Hyaluronsäure, 0,1 g bis 40 g, bevorzugt 10 g bis 30 g, besonders bevorzugt 17 g bis 19 g Harnstoff und 0,1 g bis 2 g, bevorzugt 0,1 g bis 0,2 g, besonders bevorzugt 0,125 g kolloidales Silber enthält.Composition for wound treatment in the human field, characterized in that it per 100 g of composition 0 g to 0.9 g, preferably 0.01 g to 0.15 g, particularly preferably 0.05 g to 0.07 g of hyaluronic acid, 0.1 g to 40 g, preferably 10 g to 30 g, particularly preferably 17 g to 19 g of urea and 0.1 g to 2 g, preferably 0.1 g to 0.2 g, particularly preferably 0.125 g of colloidal silver. Verwendung der Zusammensetzung für Wundbehandlungen nach Anspruch 1 als Spray.Use of the composition for wound treatment according to claim 1 as a spray. Verwendung der Zusammensetzung für Wundbehandlungen nach Anspruch 2 in einer Knopfsonde.Use of the composition for wound treatment according to claim 2 in a button probe. Verwendung der Zusammensetzung für Wundbehandlungen nach Anspruch 1 als Salbe oder Creme.Use of the composition for wound treatment according to claim 1 as an ointment or cream.
DE102007044582A 2007-09-19 2007-09-19 Composition for wound treatment in the human area Withdrawn DE102007044582A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102007044582A DE102007044582A1 (en) 2007-09-19 2007-09-19 Composition for wound treatment in the human area
PCT/DE2008/001083 WO2009036714A1 (en) 2007-09-19 2008-06-27 Composition for the treatment of wounds, containing at least silver and urea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007044582A DE102007044582A1 (en) 2007-09-19 2007-09-19 Composition for wound treatment in the human area

Publications (1)

Publication Number Publication Date
DE102007044582A1 true DE102007044582A1 (en) 2009-04-09

Family

ID=39938115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102007044582A Withdrawn DE102007044582A1 (en) 2007-09-19 2007-09-19 Composition for wound treatment in the human area

Country Status (2)

Country Link
DE (1) DE102007044582A1 (en)
WO (1) WO2009036714A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127647A1 (en) * 2009-05-08 2010-11-11 Deckner Peter G Compositions for wound treatment in the human and veterinary field
SE0901216A1 (en) 2009-09-22 2011-02-22 Small Particle Technology Gbg Ab Nanoparticles of silver
ES2421932T3 (en) 2010-03-04 2013-09-06 Neubourg Skin Care Gmbh & Co Kg Foam formulations for the treatment of skin diseases in animals
CN102343085B (en) * 2010-08-02 2014-08-27 龚森淼 Oil in water (O/W) emulsion for treating skin trauma and preparation method of oil in water emulsion
IT1402786B1 (en) * 2010-11-19 2013-09-18 Fidia Farmaceutici PHARMACEUTICAL COMPOSITIONS WITH ANTIBACTERIAL AND CICATRIZING ACTIVITIES
FR2978664B1 (en) * 2011-08-04 2014-01-10 Petcare Innovation ANTISEPTIC COMPOSITION
US11191776B1 (en) * 2013-10-23 2021-12-07 Donald Wayne Jessup Hyaluronic acid formulation
US20210196738A1 (en) 2017-12-21 2021-07-01 Prebona Ab Pharmaceutical composition comprising a colloidal dispersion and a therapeutic agent and methods and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015623A1 (en) * 1992-12-30 1994-07-21 Patent Biopharmaceutics Inc. Hyaluronic acid-urea pharmaceutical compositions and uses
DE10140623A1 (en) 2001-08-18 2003-03-06 Nawa Heilmittel Gmbh Pharmaceutical preparation for the treatment of wounds
WO2006034249A2 (en) 2004-09-20 2006-03-30 Acrymed, Inc. Antimicrobial amorphous compositions
DE102005008299A1 (en) * 2005-02-23 2006-12-28 Icb Investment Consulting Beteiligungen Gmbh Cosmetic and/or dermatological formulation, useful as e.g. antiseptic, comprises metallic silver as active agent, auxiliary- and basic- materials
DE102006032887A1 (en) * 2006-07-15 2008-01-17 Metacura Fze Use of a preparation comprising calcium hydroxide, an oil from plant-, animal- or mineral origin or a synthetic oil obtained from such oils, to care skin wound and to promote skin re-formation or regeneration
DE102006045389A1 (en) * 2006-09-26 2008-03-27 Maxim Markenprodukte Gmbh & Co. Kg Topically acting dermatological humectant comprises hyaluronic acid and panthenol in the multilamellar layers of hydrogenated liposomes
WO2008075207A2 (en) * 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369997B (en) * 2000-12-12 2004-08-11 Johnson & Johnson Medical Ltd Dressings for the treatment of exuding wounds
US20050281806A1 (en) * 2004-06-16 2005-12-22 Collegium Pharmaceutical, Inc., Delaware Compositions for topical enzymatic debridement

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015623A1 (en) * 1992-12-30 1994-07-21 Patent Biopharmaceutics Inc. Hyaluronic acid-urea pharmaceutical compositions and uses
DE10140623A1 (en) 2001-08-18 2003-03-06 Nawa Heilmittel Gmbh Pharmaceutical preparation for the treatment of wounds
WO2006034249A2 (en) 2004-09-20 2006-03-30 Acrymed, Inc. Antimicrobial amorphous compositions
DE102005008299A1 (en) * 2005-02-23 2006-12-28 Icb Investment Consulting Beteiligungen Gmbh Cosmetic and/or dermatological formulation, useful as e.g. antiseptic, comprises metallic silver as active agent, auxiliary- and basic- materials
WO2008075207A2 (en) * 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
DE102006032887A1 (en) * 2006-07-15 2008-01-17 Metacura Fze Use of a preparation comprising calcium hydroxide, an oil from plant-, animal- or mineral origin or a synthetic oil obtained from such oils, to care skin wound and to promote skin re-formation or regeneration
DE102006045389A1 (en) * 2006-09-26 2008-03-27 Maxim Markenprodukte Gmbh & Co. Kg Topically acting dermatological humectant comprises hyaluronic acid and panthenol in the multilamellar layers of hydrogenated liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Römpp, Lexikon Chemie, 10. Auflage, Georg Thieme Verlag, Stuttgart/New York

Also Published As

Publication number Publication date
WO2009036714A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
DE102007044582A1 (en) Composition for wound treatment in the human area
DE60020342T2 (en) DEEP-PUNCHING ANTIMICROBIAL COMPOSITIONS
DE29923848U1 (en) Preparations for the use of anti-inflammatory, in particular antiseptic active substances and / or active substances promoting wound healing in the upper respiratory tract and / or the ear
EP2214658A1 (en) Osmolyte-containing preparation for use in case of dry mucous membranes
DE10340277A1 (en) Personal care products containing silver agglomerates
DE60123100T2 (en) HONEY CONTAINING PHARMACEUTICAL COMPOSITION FOR WOUND TREATMENT
DE102008031023A1 (en) Foam skin care cream
DE1804801C3 (en) Acne treatment agents
DE3828044A1 (en) SILVER-SULFADIAZIN-CONTAINING MEANS FOR THE LOCAL EXTERNAL THERAPY OF HERPES LABIALIS, HERPES GENITALIS, HERPES CORPORIS, ZOSTERS (HERPES ZOSTER, WINCH POAKS AND EKZEMA HERPETICATUM AND BURNS 11TH AND 111TH DEGREES IN THE FIELD OF HUMAN MEDICINE
EP2886131B1 (en) Transparent gel
DE102007044583A1 (en) Composition, useful for wound treatment in veterinary field, as spray in button probe, and as ointment or cream, comprises hyaluronic acid, urea and colloidal silver
DE2447627C3 (en) Antimicrobial preparation
DE102005006104A1 (en) Aqueous based agents, useful as e.g. cosmetic disinfectant and cleaner, comprises inorganic alkali- and/or alkaline- earth salts, monovalent alcohols, cationic surfactants and optionally additives and/or auxiliary materials
DE102007044202A1 (en) Composition, useful for wound treatment, preferably poor or non-healing open wounds in humans, comprises hyaluronic acid, urea, and colloidal silver
DE202020002122U1 (en) Disinfectant and anti-virus static
DE102016007211A1 (en) Wound healing products in the human and veterinary field
DE3049038C2 (en)
DE102007014375A1 (en) oleylphosphocholine
DE1492023A1 (en) Skin care products
DE4134888C2 (en) Use of an oil bath as a bath additive to promote wound healing
DE202009013734U1 (en) Mineral powder mixture
DE102012000416A1 (en) Topical composition, useful for treating wounds, preferably open wounds and ulcers, comprises fusafungine and/or one of its derivative and onion extract
WO2000025763A2 (en) Agents containing phenol derivatives having an inhibiting effect on the proliferation of tumour cells
DE10140623A1 (en) Pharmaceutical preparation for the treatment of wounds
DE102021118368A1 (en) Traditional Chinese medicinal composition and method of production

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8139 Disposal/non-payment of the annual fee